FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients

被引：0
|
作者：
Salvatore, Lisa
Loupakis, Fotios
Cremolini, Chiara
Schirripa, Marta
Masi, Gianluca
Antoniotti, Carlotta
Fornaro, Lorenzo
Sensi, Elisa
Lupi, Cristiana
Bergamo, Francesca
Lonardi, Sara
Zagonel, Vittorina
Fontanini, Gabriella
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Pisa, Dipartimento Chirurg, Div Anat Patol, Pisa, Italy
[4] IRCCS, Ist Oncol Veneto, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3585
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [2] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [3] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [4] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [5] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    [J]. ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [6] REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Baldi, Giacomo Giulio
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Stasi, Irene
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [7] Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI
    Vasile, E.
    Masi, G.
    Loupakis, F.
    Cupini, S.
    Baldi, G. G.
    Salvatore, L.
    Fornaro, L.
    Pfanner, E.
    Ricci, S.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [8] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [9] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [10] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Kito, Yosuke
    Satake, Hironaga
    Taniguchi, Hiroya
    Yamada, Takeshi
    Horie, Yoshiki
    Esaki, Taito
    Denda, Tadamichi
    Yasui, Hisateru
    Izawa, Naoki
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Mori, Keita
    Yamazaki, Kentaro
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
12345